Journal Logo



Fuji, S.1; Oshima, K.2; Ohashi, K.3; Sawa, M.4; Saito, K.5; Eto, T.6; Tanaka, M.7; Onizuka, M.8; Nakamae, H.9; Shiratori, S.10; Ozawa, Y.11; Hidaka, M.12; Nagamura-Inoue, T.13; Tanaka, H.14; Fukuda, T.15; Ichinohe, T.16; Atsuta, Y.17, 18; Ogata, M.19

doi: 10.1097/
Simultaneous Sessions I: Alternative donor transplantation

1Department of Hematolgoy, Osaka International Cancer Institute, Osaka

2Department of Hematolgoy, Jyoban Hospital, Fukushima

3Hematolgoy Division, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo

4Department of Hematology and Oncology, Anjo Kosei Hospital, Aichi

5Hematopoietic cell therapy center, Jikei University School of Medicine, Tokyo

6Department of Hematolgoy, Hamanomachi Hospital, Fukuoka

7Department of Hematolgoy, Kanagawa Cancer Center

8Department of Hematology and Oncology, Tokai University School of Medicine, Kanagawa

9Department of Hematolgoy, Osaka City University Hospital, Osaka

10Department of Hematolgoy, Hokkaido University Hospital, Supporo

11Department of Hematolgoy, Japanese Red Cross Nagoya First Hospital, Nagoya

12Department of Hematolgoy, National Hospital Organization Kumamoto Medical Center, Kumamoto

13Department of Cell Processing and Transfusion, Institute of Medical Science, University of Tokyo, Tokyo

14HLA Laboratory, Kyoto

15Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo

16Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima

17Department of Healthcare Administration, Nagoya University Graduate School of Medicine

18Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya

19Department of Hematolgoy, Oita University Hospital, Oita, Japan

Back to Top | Article Outline


Cord blood transplant (CBT) is an effective treatment for hematological diseases. Graft failure (GF) remains a major complication of CBT. Although presence of pre-transplant donor-specific anti-HLA antibody (DSA) was reported to be associated with an increased risk of GF after CBT, data is still limited.

Back to Top | Article Outline


In order to clarify the impact of pre-transplant DSA, we conducted a retrospective analysis of recipients of CBT with pre-transplant anti-HLA antibody using the database of Japan Society for Hematopoietic Cell Transplantation (JSHCT).

Back to Top | Article Outline


Data for recipients of CBT with pre-transplant anti-HLA antibody from 2010 to 2014 were obtained from the Transplant Registry Unified Management Program. Additional data such as detailed information about anti-HLA antibody were collected. This study was approved by the institutional review boards of the JSHCT and Oita University.

Back to Top | Article Outline


In total, 343 patients who received CBT with detailed information about anti-HLA antibody were included in the further analysis. Median age was 51 years (range, 0 to 71). Regarding DSA, 25 patients had mean fluorescence intensity (MFI) >1000 (DSA-positive group) and 318 patients had MFI<1000 (DSA-negative group). Cumulative incidence of neutrophil engraftment at 60 days after CBT was 75.7% (95% CI, 70.6-80.1) in the DSA-negative group and 56.0% (95% CI, 34.1-73.1) in the DSA-positive group (P = 0.03, Figure). Grouped according to the HLA class of DSA, cumulative incidence of neutrophil engraftment was 71.4% in patients with DSA against HLA class II antigen (n = 14), 44.4% in those with DSA against HLA class I antigen (n = 9), 0% in those with DSA against both HLA class I and class II antigens (n = 2). Stratified according to the achievement of neutrophil engraftment, the probabilities of overall survival at 1 year after CBT were 62.7% (95% CI, 56.2-68.5) in the engrafted patients and 19.5% (11.8-28.5) in the non-engrafted patients (P < 0.001).



Back to Top | Article Outline


Our study is a largest cohort of CBT recipients with pre-transplant anti-HLA antibody. Pre-transplant DSA was associated with an increased risk of GF. The importance of target HLA antigen should be clarified in the future study.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.